Form 4: Edesa Biotech CEO Increases Stake with RSU Grant

Edesa Biotech's CEO, Pardeep Nijhawan, reported the acquisition of 8,766 common shares through a restricted share unit grant.

Summary

• Pardeep Nijhawan, the Chief Executive Officer, Director, and 10% Owner of Edesa Biotech, Inc. (EDSA), acquired 8,766 common shares.
• The acquisition occurred on December 1, 2025, and represents a grant of restricted share units (RSUs) that vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.
• The acquisition price for these shares was $0.
• Following this transaction, Nijhawan directly beneficially owns 491,378 common shares.
• Indirect beneficial ownership includes 341,702 common shares held by Pardeep Nijhawan Medicine Professional Corporation, 32,609 common shares held by The New Nijhawan Family Trust 2015, 32,013 common shares held by The Digestive Health Clinic Inc., and 53,104 common shares held by 1968160 Ontario Inc.

Sentiment

Score: 7

Explanation: The filing indicates an increase in the CEO's direct ownership through an equity grant, which is generally a positive signal for alignment of interests, though it's a routine compensation event rather than a market purchase.

Positives

• CEO Pardeep Nijhawan increased his direct beneficial ownership in Edesa Biotech by 8,766 common shares, signaling continued alignment of management interests with shareholders.
• The grant of restricted share units (RSUs) is a standard component of executive compensation, reinforcing long-term commitment.

Future Outlook

NA

Management Comments

• Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Industry Context

This Form 4 filing is a routine disclosure of insider share ownership changes and does not provide specific industry context or trends. It reflects an individual executive's compensation and equity stake in the company.

Related Party Transactions

• The indirect ownership through Pardeep Nijhawan Medicine Professional Corporation, The New Nijhawan Family Trust 2015, The Digestive Health Clinic Inc., and 1968160 Ontario Inc. represents holdings by entities related to the reporting person, with beneficial ownership disclaimed except to the extent of pecuniary interest.

Stakeholder Impact

• Shareholders: Increased alignment of the CEO's interests with shareholders due to an increased equity stake in the company.

Key Dates

Recommendation

This Form 4 filing details a routine grant of restricted share units to the CEO, increasing his beneficial ownership. While this aligns management's interests with shareholders, it does not provide new fundamental information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. It's an expected compensation event.

Keywords

Edesa Biotech, EDSA, Pardeep Nijhawan, Form 4, Insider Trading, Restricted Share Units, Equity Incentive Plan, CEO, Director, 10% Owner, Share Ownership